Your browser doesn't support javascript.
loading
Heterologous SARS-CoV-2 booster vaccine for individuals with hematological malignancies after a primary SARS-CoV-2 mRNA vaccine series.
Sherman, Amy C; van Haren, Simon D; Borberg, Ella; Swank, Zoe; Aleissa, Muneerah; Tong, Alexandra; Rooks, Rebecca; Kanwal, Urwah; Levine, Hannah; Yates, Bridget; Izaguirre, Natalie; Ryff, Kevin; Thomas, Sanya; Parisi, Lindsey; Li, Xiaofang; Walt, David R; Levy, Ofer; Walsh, Stephen R; Issa, Nicolas C; Baden, Lindsey R.
Afiliação
  • Sherman AC; Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, USA; Dana-Farber Cancer Institute, Boston, MA, USA; Precision Vaccines Program, Department of Pediatrics, Boston Children's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA. Electronic address: acsherman@bwh
  • van Haren SD; Precision Vaccines Program, Department of Pediatrics, Boston Children's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
  • Borberg E; Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA; Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, USA.
  • Swank Z; Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA; Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, USA.
  • Aleissa M; Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, USA; Dana-Farber Cancer Institute, Boston, MA, USA; Department of Pharmacy Practice, College of Pharmacy, Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia.
  • Tong A; Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, USA.
  • Rooks R; Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, USA; Emory School of Medicine, Atlanta, GA, USA.
  • Kanwal U; Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, USA.
  • Levine H; Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, USA.
  • Yates B; Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, USA.
  • Izaguirre N; Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, USA.
  • Ryff K; Precision Vaccines Program, Department of Pediatrics, Boston Children's Hospital, Boston, MA, USA.
  • Thomas S; Precision Vaccines Program, Department of Pediatrics, Boston Children's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
  • Parisi L; Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, USA.
  • Li X; Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, USA.
  • Walt DR; Harvard Medical School, Boston, MA, USA; Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA; Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, USA.
  • Levy O; Precision Vaccines Program, Department of Pediatrics, Boston Children's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Broad Institute of MIT & Harvard, Cambridge, MA, USA.
  • Walsh SR; Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
  • Issa NC; Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, USA; Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
  • Baden LR; Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, USA; Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
Vaccine ; 2024 Jun 10.
Article em En | MEDLINE | ID: mdl-38862310
ABSTRACT
Heterologous COVID-19 vaccine boosters have not been evaluated for patients with hematological malignancies. A Novavax booster was administered for 56 individuals with hematological malignancies who had received a primary COVID-19 series and prior boosters with mRNA vaccines only. Blood specimens were obtained at baseline (pre-vaccine), 28 days, and 168 days after vaccination with the Novavax booster. The median fold change of anti-Spike IgG was 1.02 (IQR 0.79, 1.3) between baseline and Day 28. Circulating Spike protein-specific B cells increased 1.4-fold at Day 28 (p < 0.05). Increases in antibody and T cell responses were modest without significance, with a waning of humoral and cellular responses at 168 days after vaccination.
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article